Applie

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10790574		
Filing Date		2004-03-01		
First Named Inventor	John	D. Mehr		
Art Unit		2153		
Examiner Name				
Attorney Docket Numb	er	MS307141.01/MSFTP573US		

	U.S.PATENTS Remove							
		Kind Code ¹	Issue Date Name of Patentee of Applicant		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6742047		2004-05-25	Michael Man-Hak Tso			
	2	6314421		2001-11-06	Sharnoff, et al.			
	3	6421709		2002-07-16	McCormick, et al.			
	4	6321267		2001-11-20	Albert L. Donaldson			
	5	6701440		2004-03-02	Km, et al.			
	6	6167434		2000-12-26	Stephen Y. Pang			
	7	6732157		2004-05-04	Gordon, et al.			
	8 6643686 2003-11-04		2003-11-04	Robert J. Hall				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10790574		
Filing Date		2004-03-01		
First Named Inventor John		D. Mehr		
Art Unit		2153		
Examiner Name				
Attorney Docket Number		MS307141.01/MSFTP573US		

	9	6928465		2005-08-09	Jerry Brett Earnest					
If you wis	h to a	dd additional U.S. Pater	t citatio	n information p	lease click the Add button.		Add			
	U.S.PATENT APPLICATION PUBLICATIONS Remove									
Examiner Initial*	aminer Cite Publication Number Kind Publication Name of Patentee or Applicant Releva				Releva		Lines where ges or Relevan			
	1	20010046307	A1	2001-11-29	Ping Wah Wong					
	2	20020073157	A1	2002-06-13	Newman, et al.					
	3	20040199594	A1	2004-10-07	Radatti, et al.					
	4	20020091738	A1	2002-07-11	Rohrabaugh, et al.					
	5	20040073617	A1	2004-04-15	Milliken, et al.					
6		20030229672	A1	2003-12-11	Daniel Mark Kohn					
-	7	20050015455	A1	2005-01-20	Gary G. Liu					
If you wis	h to a	dd additional U.S. Publis	shed Ap		n information please click the Add FENT DOCUMENTS		Add Remove			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10790574	
Filing Date		2004-03-01	
First Named Inventor John		D. Mehr	
Art Unit		2153	
Examiner Name			
Attorney Docket Numb	er	MS307141.01/MSFTP573US	

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							
If you wisi	h to a	dd additional Foreign	Patent Documer	nt citation	information p	lease click the Add butto	n Add	
			NON-PATI	ENT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No					Ţŝ		
	1							
If you wisi	h to a	dd additional non-pate	ent literature doc	ument cit	tation informa	tion please click the Add	button Add	
EXAMINER SIGNATURE								
Examiner	Examiner Signature Date Considered							
	*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 2 Applicant is to place a check mark here if English language translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10790574
			2004-03-01 D. Mehr
First Named Inventor John I		John	
	Art Unit		2153
Examiner Name Attorney Docket Number			
		ar .	MS307141 01/MSFTP573US

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 137(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Himanshu S. Amin/	Date (YYYY-MM-DD)	2006-11-07
Name/Print	Himanshu S. Amin	Registration Number	40894

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.0 and 3T CFR.

1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2211-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.